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ABSTRACT 
Background 
Hepatitis C (HCV) in South Africa is incompletely characterised and understood. 
Epidemiological and clinical data  will better inform our understanding and assist national 
policy decision making. On the background of more than two decades of clinical 
challenges in HCV management, the advent of direct acting antivirals (DAA) now makes 
HCV elimination plausible. To better understand the base from which we come, we 
elected to review and characterise our HCV experience at Groote Schuur Hospital (GSH) 
in the Pegylated interferon (Peg-IFN) and Ribavirin (RBV) management era. 
 
Methods 
Patients with chronic HCV attending GSH Liver Clinic from 2002 to 2014, were included, 
in the analysis. Relevant data were extracted from a registry and existing clinical records 
accessed. Two brands of Peg-IFN were available and those treated with the first 
generation add-on protease inhibitor, telaprevir, were included. 
  
Results 
238 patients were included in the analysis, median age of 47 (IQR 37-58) years, men 
60.5%.  Men were significantly younger than women, 43.5 (35-52) vs 55 (42-64) years, 
respectively, p<0.0001. Ethnically, the majority were white (55.9%) or mixed-ancestry 
(21.8%), 16.4% were HIV co-infected, 3.7% hepatitis B (HBV) co-infected and 0.4% triple 
infected with HCV, HBV and HIV. The most likely mode of HCV acquisition was 
blood/blood product exposure prior to 1992 (32.8%) and injecting drug use (IDU) 17.6%, 
while 30.3%, had no clear risk factor identifiable. Genotypes (GT) 1 to 5 were observed 
with GT-1 (34.9%) predominating. In those biopsied, (n=90), 30% ≥F3 fibrosis, with 15.6% 
cirrhotic. With IL28B polymorphisms, heterozygous CT (23.9%) and CC genotype 
(15.5%), were most frequent. 32.6% accessed Peg-IFN/Ribavirin-based therapy, 6.5% 
(n=5) with add-on telaprevir. GT-1 (35.1%) was most prevalent in the treatment group, 
followed by GT-3 (26%) and GT-5 (18.2%); 10% were HIV co-infected. Overall  SVR rate 
was 75.3% with 37% of GT-1 not achieving SVR; 49.4% experienced adverse events 
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including cytopaenias (32.5%) and depression (15.6%) with 15.6% requiring 
erythropoietin for anaemia and 15.6% GM-CSF for neutropaenia.  
 
Conclusion 
HCV patients in the Peg-IFN/Ribavirin management era typified the epidemiology of HCV.  
GT distribution was pangenotypic and treatment outcomes were encouraging despite 
treatment challenges. Patient selection, IL28B and sensible cytopaenia support, likely 
accounted for this. However numbers treated were limited and the DAA era of therapy 
allows for a rapid expansion of therapy with now growing numbers of patients and a 
changing local epidemiology.  
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INTRODUCTION 
 
In 2016 at the 69th World Health Assembly, the World Health Organisation’s (WHO) first 
Global Health Sector Strategy to eliminate viral hepatitis was approved and adopted by 
member states. The aim of the strategy is to eliminate viral hepatitis by 2030 being defined 
as a 65% reduction in mortality from end-stage liver disease and a 90% reduction in the 
incidence of new infections. (1)  Up to 2014, the standard of care for the management of 
hepatitis C virus (HCV) for more than a decade, prior to the advent of the direct-acting 
antiviral (DAA) era of therapy, was Pegylated interferon and Ribavirin (Peg-IFN/RBV). 
The response to therapy was variable and dependent on a number of viral and host 
factors. In addition to a variable response, adverse events and intolerability of therapy 
was significant. Overall, approximately 50% of patients responded to therapy with a 
sustained virological response (SVR), defined then as being hepatitis C polymerase chain 
reaction (PCR) negative 24 weeks after the end of treatment (EOT) and were cured. Since 
the advent of the DAAs, all oral therapies are possible and in excess of 90% of patients 
can be cured, making the goal of elimination achievable provided that HCV-infected 
individuals are identified and appropriately linked to care. 
 
The global HCV prevalence is approximately 1% and translates to an estimated 71.1 
million people with active hepatitis C viraemia. HCV is a leading cause of chronic liver 
disease worldwide and the global burden of disease continues to increase as those 
infected develop the potential long-term complications of cirrhosis, hepatocellular 
carcinoma (HCC), liver failure and death. (2) Notably, 36.7 million people are currently 
living with Human Immunodeficiency Virus (HIV) infection globally. (3) HCV thus has a 
greater net burden than HIV (4), a fact not often appreciated given the infection is 
invariably silent for 2 - 3 decades before long-term complications develop. Of note, HIV 
co-infection significantly alters the natural history of hepatitis C resulting in accelerated 
fibrosis and progression to cirrhosis and an increased risk of HCC as well as reduced 
response to interferon-based therapy. (5-8) 
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EPIDEMIOLOGY OF HCV IN SUB-SAHARAN AFRICA AND SOUTH AFRICA 
 
Sub-Saharan Africa has a significant HCV disease burden and accounts for 
approximately 15-20% of the burden of infections globally. Good  epidemiological data is 
limited and reported prevalences are inconsistent. (9) A suggested seroprevalence is 3% 
with approximately 10.1 million individuals being viraemic, as per modelled data. (10) The 
region is pan-genotypic with genotypes 1 and 4 encountered most frequently. (4) 
 
Epidemiology and prevalence in South Africa of chronic hepatitis C remains poorly 
characterised. The suggested prevalence rates in South Africa are often based on blood 
donor data which is a poor representation of the real HCV burden given that many high 
risk groups are excluded from being donors. Few data exists on defined cohorts of 
patients with chronic HCV in South Africa, as regards: genotype distribution, disease 
presentation and progression, access to treatment, long-term outcomes and response to 
treatment. The prevalence of HCV viraemia in South Africa in 2015, is likely between 0.4 
and 0.9% in the general population but is greater in high-risk groups especially people 
who inject drugs (PWID). It is estimated that 600 000 to 800 000 South Africans are 
viraemic for HCV. (2) Recent data from a large national screening study of key and 
vulnerable populations determined a HCV viraemic rate of 44% in people who inject drugs 
(PWID), 6% in people who use drugs (PWUD), and 2% in men who have sex with men 
(MSM). There was marked geographical and regional variability with the highest rates in 
Pretoria and similar, albeit lower, rates in Cape Town, Johannesburg, Durban and Port 
Elizabeth. Genotypes 1a and 3a predominated with a handful of genotype 4 observed. 
HIV co-infection was frequent at 12.2% in PWID. (11) 
 
HEPATITIS C VIROLOGICAL CHARACTERISTICS 
 
Hepatitis C was first observed and described by Feinstone et al. in 1975, and  identified 
as the commonest cause of transfusion-associated hepatitis.  It was named  non-A, non-
B hepatitis (NANBH) given that hepatitis A and hepatitis B were the only identified 
hepatitis viruses at the time. (12) In 1989, in a laboratory at Cheiron, Choo and his 
colleagues, cloned and sequenced the genome of hepatitis C. (13, 14)  
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HCV is a single-stranded positive-sense ribonucleic acid (RNA) virus belonging to the 
flaviridae family and replicates almost exclusively in hepatocytes. The viral RNA 
polymerase lacks a “proofreading” ability which results in the simultaneous presence of 
different viral variants, defined as quasi-species in the same host. The genome 
undergoes constant mutation and often escapes human immunological detection and 
elimination leading to chronic infection. (15, 16) Through phylogenetic analysis, the 
genetic heterogeneity was categorised into 7 major genotypes and 67 subtypes. (17) 
Genotypes 1 and 3 are the most prevalent globally, and account for 46% and 30% of 
infection, respectively. Genotypes 2, 4 and 6 comprise 9%, 8% and 6% of all infections, 
respectively and genotype 5 has a 1% prevalence. Genotype 7 has only been observed 
in a few individuals in Central Africa. (18) The distribution of genotypes in Sub-Saharan 
Africa varies and is essentially a pan-genotypic region with genotypes 1 and 4 
predominating. (19) In South Africa, the most prevalent genotype in blood donors is 
genotype 1 (34%). However, in the overall population, the commonest are genotypes 5a 
and 1 with a prevalence of 35% and 31%, respectively and genotypes 2, 3 and 4 
comprising 2%, 14% and 14%, respectively with 4% having mixed genotypes. (9) This 
high degree of genetic heterogeneity determines treatment regimens and creates a major 
challenge for the development of HCV vaccines. (17) 
 
ROUTES OF TRANSMISSION AND HIGH RISK GROUPS 
 
HCV is most efficiently transmitted through parenteral inoculation. Prior to the 
implementation of routine screening of blood donor products in the early 1990’s, blood or 
blood product transfusions posed a major risk factor for the transmission of HCV infection 
in developed countries. This risk was substantially reduced following the implementation 
of blood product screening, (20) which was introduced in South Africa in 1992. 
Unfortunately, some low and middle income countries still have inconsistent or sub-
standard testing, usually due to financial implications of screening. (21) Other routes of 
transmission of HCV include injecting drug use, tissue and organ transplants, unsafe 
medical procedures or injection practices, health care worker (HCW) parenteral exposure 
(eg. needle-stick injuries), traditional scarification, body piercings, sexual transmission 
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(MSM mainly) and mother-to-child transmission (MTCT) especially in HIV/HCV co-
infected pregnant women. (22) 
 
SCREENING FOR HCV 
 
There is limited data as regards the cost-effectiveness of HCV screening approaches in 
low and middle income countries. Review of the available literature suggests that testing 
of high-risk groups such as prisoners, PWID, MSM and HIV-infected individuals is likely 
cost-effective. Outside the setting of populations known to have a high HCV prevalence, 
routine screening has not been proven to be cost-effective. (23) With minimal data 
available as to prevalence rates and modes of transmission in South Africa, planning cost-
effective screening programmes is challenging. A recent review describes the prevalence 
and risk factors among South African MSM who inject drugs. (24) Here, the suggested 
seroprevalence was 27%. Other at risk populations in South Africa such as people living 
with HIV/AIDS (PLWHA), transgender individuals, sex workers and prisoners, must be 
included in future screening programmes. (24) Awareness campaigns encouraging 
routine testing in high-risk groups needs to be instituted as well as giving PWID access 
to syringe and needle exchange programmes as well as assisting with opiate addiction 
via opiate drug-substitution therapy. (25) De-stigmatisation plays a key role in addressing 
this considerable burden of disease globally. (24) 
 
The Western Province Blood Transfusion Service (WPBTS) which services the Western 
Cape and the South African National Blood Service (SANBS) which services the rest of 
South Africa perform the only formal HCV screening in South Africa. These blood donor 
services practice judicious blood and blood product screening, including pan nucleic acid 
tests, which has virtually eliminated transfusion-associated viral hepatitis and HIV. Donors 
who are screened and found to be HIV, HCV or HBV infected are appropriately informed 
and referred for further evaluation and management. The implementation of screening 
programmes outside the blood transfusion service, does not exist. There is urgent need 
for the implementation of routine screening in the appropriate populations as well as 
linkage to care and treatment, appropriate follow up and ultimately cure. 
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In order to make routine screening for HCV more accessible and cost-effective, the WHO 
prequalified its first point-of-care (POC) rapid diagnostic tests in 2016/2017. The SD 
BIOLINE HCV test and the OraQuick HCV Rapid Antibody Test both have sensitivities 
and specificities approaching 100% when compared to laboratory-based testing. (26) 
Where laboratories are accessible, screening is best performed using immunoassays 
such as an enzyme-linked immunosorbent assay (ELISA). If this is positive, a 
confirmation is required using HCV-RNA nucleic acid testing (NAT) to establish whether 
there is active viraemia. (4) Quantitative NAT has been used to measure HCV viral load 
and monitor treatment response. Qualitative testing allows for rapid and sensitive 
detection of virus below a defined threshold. HCV core (p22) antigen (HCVcAg) is an 
alternative to detect active viraemia as well as being used to monitor treatment response 
and confirm SVR. (27) 
 
CLINICAL MANIFESTATIONS AND NATURAL HISTORY OF DISEASE 
 
Hepatitis C has acute and chronic clinical manifestations and the course of the infection 
varies among individuals. The acute infection is often asymptomatic and thus goes 
undetected in the majority of infected individuals. The long asymptomatic course makes 
it important to establish routine screening in high-risk populations. 
 
Clinical manifestations can present about 8 weeks following exposure and symptoms 
include anorexia, fatigue, jaundice and malaise. HCV rarely causes fulminant hepatic 
failure. (15) Acute HCV infection is characterised by the appearance of HCV RNA, HCV 
core antigen, and subsequently HCV antibodies within six months of infection with HCV. 
It is estimated that approximately 20 - 30% of HCV infected patients will undergo 
spontaneous viral clearance. Certain factors which reduce the likelihood of spontaneous 
clearance include injection drug use, HIV co-infection, excessive alcohol consumption, 
black race, non-genotype 1 infection and asymptomatic presentations. (28) The IL28B 
polymorphism and DQB1*0301 allele of the histocompatibility complex class II, are two 
genetic host factors with a strong association with spontaneous viral clearance. (29) 
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Chronic HCV infection occurs in 45 - 84% of infected individuals after acute exposure with 
chronicity defined as the persistence of HCV RNA within blood for more than six months. 
Chronic HCV infection is a slowly progressive disease with chronic hepatic necro-
inflammation resulting in cirrhosis in approximately 20% of patients over two to three 
decades of infection. Once cirrhosis is established, HCC develops in 1 - 4% of these 
individuals per year and the annual risk of developing decompensated liver failure is 3 - 
6% per year. (29, 30)  
 
Chronic HCV infection is also associated with extra-hepatic manifestations. These include 
sicca syndrome, porphyria cutanea tarda, lichen planus, type 2 diabetes, and non-
Hodgkin’s lymphoma. Between 15% and 30% of individuals will have circulating 
cryoglobulins and 5-25% of these individuals will develop essential cryoglobulinaemia, 
systemic vasculitis, peripheral neuropathy, Raynaud’s phenomenon, and 
membranoproliferative glomerulonephritis. (31) 
 
Progression to fibrosis is variable and there are numerous co-factors which increase an 
individual’s risk. These factors include HIV or HBV co-infection, acquiring infection at an 
older age, male gender, excess alcohol consumption, insulin resistance, type 2 diabetes 
mellitus, immunosuppressive therapy, and host genetic factors. (29) Achieving an SVR  
is defined as having no viral RNA present 24 weeks after completing Peg-IFN/RBV 
therapy or 12 weeks after completing DAA therapy. SVR reduces complications 
associated with chronic liver disease as well as the extra-hepatic complications, thereby 
improving quality of life and reducing morbidity and mortality. (29) 
 
With Peg-IFN/RBV therapy, liver biopsy was essential to assess both the degree of necro-
inflammation (histological grade) and the presence and stage of liver fibrosis as well as 
other negative co-factors such as steatohepatitis and iron overload as this determined 
both the indication for therapy as well as the likelihood of an SVR. In the DAA era, staging 
liver disease remains important, because it influences treatment duration and whether 
RBV is required as add-on therapy, but this is usually assessed non-invasively with the 
Fibroscan®. Prior to non-invasive methods such as Fibroscan®, histological evaluation 
of the liver biopsy remained the gold standard for determining the activity of HCV-related 
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liver disease and assessing fibrosis, thereby predicting prognosis and likelihood of 
progression of disease. Histologically HCV infection consists of lymphocyte infiltration in 
the parenchyma, lymphoid follicles in portal areas, and reactive bile duct changes. (32) 
Biopsy can also be useful in excluding other causes of liver disease (autoimmune 
hepatitis, alcoholic liver disease, drug-related liver injury, iron overload and 
steatohepatitis). 
 
Different histological scoring systems for hepatitis C infection are available including the 
Batts-Ludwig, METAVIR and Ishak systems. The METAVIR system – the most widely 
used – incorporates both a grading and staging system. The grading system assesses 
necro-inflammation. The staging system assesses the degree of fibrosis. The grades 
range from 0-4 with 0 being no activity, 1 mild activity, 2 moderate activity and 3 or 4 
varying severe activity. In the staging system (0-4), stage F1 denotes minimal fibrosis, F2 
scarring that extends outside the areas that contain blood vessels, F3 bridging fibrosis 
and F4 denotes cirrhosis. (33) 
 
THE HEPATITIS C TREATMENT ERAS 
 
INTERFERON-BASED THERAPIES 
 
In the early 1990’s, the potential benefits of interferon-alfa therapy (IFN-α) for HCV 
infection, was documented. Two randomised controlled trials (RCTs) using a 24-week 
course of treatment with IFN-α demonstrated that this therapy improved serum alanine 
aminotransferase (ALT) levels and liver histology. These effects were dose-dependent 
with greater improvements noted with three times weekly injections of 2 to 3MU (46-48%) 
of IFN as opposed to 1MU (28%) three times a week or control (0-8%) groups. Efficacy 
was measured at the end of therapy, while still on IFN and demonstrated that HCV RNA 
was eradicated in some patients. (34, 35) Following these outcomes the United States 
Food and Drug Administration (FDA) approved IFN-α2b for the management of chronic 
HCV in 1991. (36) Despite viral eradication with IFN therapy, the one trial demonstrated 
that 80% of responders had relapsed one year after completion of treatment (COT). (34) 
The cure rate (defined as an SVR 6 months after COT) for IFN monotherapy was between 
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15 and 20%. A few years later Ribavirin (RBV), an oral antiviral agent with an undefined 
but probable immunomodulatory action, was added to IFN therapy. The combination was 
found to be superior to IFN alone in terms of virological, biochemical and histological end 
points. RCTs demonstrated that SVR rates of  approximately 30-40% were achieved. (37, 
38) Dose reduction or treatment cessation was more often required in patients receiving 
combined IFN/RBV therapy. The most frequent reason for discontinuation of therapy in 
groups receiving IFN-monotherapy or combined IFN/RBV, was psychiatric adverse 
events and notably depression. Depression resulted in the cessation of treatment in 2-
9% of patients. (37) The RBV metabolite accumulates in red blood cells and results in a 
reversible haemolytic anaemia. It was observed that 36% of subjects developed anaemia, 
up to 20% will have a haemoglobin (Hb) level drop below 10g/dl and 8.5g/dl in 5%. (39) 
50% of subjects experience influenza-like symptoms, 25% have psychiatric symptoms of 
which 20% are severe including acute psychosis, severe depression and personality 
change. Fatigue or myalgia is experienced in 20% of patients, and gastritis or 
gastroenteritits in 10%.  (37)  
 
Pegylated interferon (Peg-IFN) was developed to enhance the half-life of IFN. There are 
two types of Peg-IFN, namely Peg-IFN-alfa-2a and Peg-IFN-alfa-2b which are equally as 
efficient. (40) From 2000 with the advent of once weekly dosed Peg-IFN, standard of care 
for the management of HCV, for almost two decades, became Peg-IFN and RBV (Peg-
IFN/RBV). The response to therapy was genotype and host factor dependent with 
significant adverse side effects and overall less than a 50% chance of a cure. SVR rates 
of 70-80% for HCV genotype 2 or 3 infections and 45-70% for other genotypes were 
documented. (41) Genotype 1 achieved much lower SVR rates of approximately 40%. 
(42, 43) In a randomised trial, over 3000 patients with chronic HCV genotype 1 infection 
were assigned to receive 48 weeks of treatment with either Peg-IFN-alfa-2b at standard 
dose (1.5 μg per kilogram of body weight per week) or a low dose (1.0 μg per kilogram 
per week), plus RBV at a dose of 800 to 1400 mg per day, or Peg-IFN-alfa-2a at a dose 
of 180 μg per week plus RBV at a dose of 1000 to 1200 mg per day. (40) The safety and 
adverse-event profiles and efficacy data were similar among subjects treated with low-
dose or standard-dose Peg-IFN-alfa-2b or Peg-IFN-alfa-2a, combined with varying RBV 
dosages. Despite improved cure rates, these regimens were associated with significant 
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adverse effects requiring dose reduction and/or cessation of therapy. The most common 
adverse effects among all three groups included influenza-like symptoms, depression and 
haematological side-effects including anaemia and neutropaenia. Between 12.5% and 
21.1% of subjects required dose reduction and 2.1-5.9% required discontinuation of 
therapy, because of neutropaenia. 23.2-28.2 % of subjects met the Hb criteria for RBV-
dose reduction (between 8.5 and 10g/dl) and between 2.1 and 3.8% required 
discontinuation of therapy, because of an Hb <8.5g/dl. Psychiatric symptoms were mild 
to moderate and resulted in treatment cessation in 1.8-2.6% of subjects.(40) 
In 2009, Dongliang Ge et al. reported that a genetic polymorphism near the IL28B gene 
on chromosome 19, encoding interferon-lambda-3 (IFN-lambda-3) was found to be 
associated with an approximately twofold greater rate of SVR in response to treatment, 
both among patients of European ancestry and African-Americans. Only individuals with 
genotype 1 were included in this study. The IL28B polymorphism is associated with both 
natural clearance of the virus as well as treatment response. (44) When genotyped at the 
IL28B polymorphism site into IL28B CC, CT or TT; the IL28B CC genotype was 
associated with a more favourable treatment response when compared to non-CC 
genotypes. (45) The presence of IL28B CC was used to decide on the suitability of a 
HCV-infected individual for Peg-IFN/RBV therapy as this polymorphism improved the 
SVR. Since the advent of the DAAs, pan-genotypic therapies are possible and SVR is 
obtainable in more than 90% of cases irrespective of IL28B polymorphisms. 
 
SOUTH AFRICAN HEPATITIS C MANAGEMENT GUIDELINES 2005 AND 2010 
 
The risk-benefit of treatment was an important consideration when making therapeutic 
decisions. Factors such as quality of life, age, co-morbidities, virological factors and 
histological assessment all influenced decision to treat. Patients at increased risk of 
developing cirrhosis required treatment.  
 
Indications for treatment (2005) 
1. Moderate or severe chronic hepatitis infection as characterised by stage F2 or F3 fibrosis 
(METAVIR scoring system) regardless of the necro-inflammatory grade and patients with 
A2 and A3 disase (METAVIR scoring system). 
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2. Mild chronic hepatitis (F0 or F1) or chronic hepatitis associated with normal 
transaminases. The long-term benefits of treatment in the absence of excessive alcohol 
consumption, HCV/HIV co-infection and obesity was not yet established. Liver 
transaminases fluctuate and these patients should be monitored every 4-6 months. 
3. Patients with compensated cirrhosis were considered for treatment on an individual basis 
in order to stabilise disease and prevent complications such as HCC. 
4. Relapsers or non-responders after IFN-monotherapy or IFN/RBV combination therapy. 
Relapse is defined as detectable HCV-RNA in serum within 6 months following the end 
of treatment (EOT). Non-response is defined as detectable HCV-RNA at the completion 
of treatment (COT).  
5. Treatment was contraindicated in patients with liver transplants.  
6. Treatment with IFN-monotherapy was strongly recommended in patients with acute HCV 
infection. Long-term effects of Peg/IFN had not yet been established in this group.  
7. Special populations: 
a. Patients with alcohol dependence needed a period of abstinence from alcohol for at least 
1 year prior to the initiation of treatment. 
b. Patients using recreational drugs required a multidisciplinary approach including 
rehabilitation programmes, psychological and psychiatric assessment. 
c. Treatment can worsen psychiatric disorders and patients with pre-existing psychiatric 
disease needed to be clinically stable prior to being treated. 
The decision to treat patients with HIV/HCV co-infection depended on liver biopsy results 
and the immune status of the patient. Patients with a CD4 count > 200, warranted 
treatment for the HCV first. In patients established on antiretroviral therapy (ARV), the 
indications to treat were based on the same histological criteria as those without HIV. 
8. Patients with HCV/HBV co-infection: a liver biopsy, HCV and HBV viral load and genotype 
were important in deciding on appropriate management.  
9. Other intercurrent disorders: 
a. Haematological: 
i. Liver biopsy was contraindicated in haemophiliacs and there was no need to change 
treatment regimens. 
ii. Thalassaemic patients: RBV was contraindicated. 
b. Renal impairment: 
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i. RBV and IFN are contraindicated in non-dialysed patients. 
ii. IFN is relatively contraindicated following renal transplant. 
 
In 2010, the following changes were made with regards to indications for treatment: 
1. The METAVIR activity score was no longer used as a criteria for therapy.  
2. Symptomatic cryoglobulinaemia was included as an indication to treat. 
The following contraindications were also included in the 2010 guidelines: 
1. Under 2 years of age 
2. Untreated thyroid disease 
3. Autoimmune conditions (including autoimmune hepatitis), known to be exacerbated by 
Peg-IFN and RBV 
4. Decompensated liver disease 
5. Severe concurrent medical conditions including coronary artery disease, cardiac 
dysfunction, hypertension, chronic obstructive airways disease or poorly controlled 
diabetes mellitus 
6. Pregnancy or patients unwilling to use adequate contraception 
7. Severe depressive illness which is not yet established on medication 
8. Hypersensitivity to medication used to treat HCV 
9. Solid organ transplantation 
 
Liver Biopsy 
Except where contraindicated, all patients being considered for treatment required a liver 
biopsy. The pre-treatment liver biopsy assisted in identifying other pre-existing liver 
conditions as well as grading fibrosis and necro-inflammatory activity. 
 
Treatment 
Drugs approved for treatment of chronic HCV included: interferon alfa-2a, interferon alfa-
2b, interferon alfacon-I, peginterferon alfa-2a, peginterferon alfa-2b and Ribavirin. 
Peg/RBV combinations: 
1. Peg-IFN-alfa-2a 180µg weekly subcutaneously (s/c) + Ribavirin (800-1200mg/day) 
2. Peg-IFN-alfa-2b (1-1.5 µg/kg/week) s/c + Ribavirin (800-1200mg/day) 
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Treatment duration: 
Genotype 1 and 4: 48 weeks of treatment. 
Genotype 2 and 3: 24 weeks of treatment. 
Genotype 5 and 6: 48 weeks of treatment. 
 
The 2010 guidelines included the following: 
Patients with genotype 1 or 4 with a delayed response (HCV RNA negative between 12 
and 24 weeks), were considered for an extended course of therapy for 72 weeks. Patients 
who received treatment through 48 to 72 weeks and have a negative HCV RNA, were 
retested 24 weeks after the EOT, to establish whether they have obtained an SVR. Due 
to a data lack, genotypes 5 and 6 were treated as genotype 1, for a duration of 48 weeks. 
Patients with genotype 2 or 3 with a delayed response (HCV RNA negative between 12 
and 24 weeks), were considered for an extended course of therapy for 48 weeks. These 
patients who had a negative HCV RNA at the EOT, had repeat testing performed 24 
weeks later to establish whether they had obtained an SVR. 
 
Treatment indications 
 Previously untreated patients without contraindications for therapy. 
 Patients with HIV/HCV co-infection who have received no prior therapy for HCV. HCV 
therapy should follow the initiation of ARV and close attention needs to be paid to drug-
drug interactions. 
 Relapsers after IFN-monotherapy. 
 Non-responders to IFN-monotherapy. 
Peg-IFN monotherapy was indicated in patients where RBV was contraindicated. 
Standard IFN monotherapy was indicated in patients with acute HCV infection or patients 
on dialysis. Liver transplantation was indicated in patients with decompensated cirrhosis. 
 
Supportive measures 
Serious adverse effects such as neutropaenia, anaemia and thrombocytopaenia, 
required dose-adjustment or discontinuation of treatment. 
1. Neutropaenia could be managed with Granulocyte-Colony Stimulating Factor (GM-CSF).  
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2. Anaemia could be managed by concomitant administration of erythropoietin and 
maintaining the patient on 80% of the dose. 
 
Obesity 
Obesity is a risk factor for steatosis and increases the progression of fibrosis. HCV also 
aggravates insulin resistance. Patients with a BMI>25kg/m2, are encouraged to lose 
weight prior to the initiation of therapy. 
 
Vaccination 
Patients who are not immunised, should receive vaccination against HAV and HBV. 
 
Venesection 
Venesection is recommended in patients who have iron overload present on liver biopsy. 
 
Evaluation prior to initiating treatment 
A full physical examination including the eyes and urinalysis is mandatory prior to initiating 
treatment.  
Baseline blood tests required include: 
Haematology: Full blood count (FBC), INR and PTT. 
Chemistry: Electrolytes, urea, creatinine, liver function tests, uric acid, cholesterol, alpha-
fetoprotein (AFP) 
Thyroid function tests: TSH and FT4. 
HCV-RNA, genotype and viral load. 
HIV ELISA 
HBsAg, anti-HBs, HBcore IgG 
A pregnancy test was to be done 1 day prior to starting treatment in all female patients 
and in all female partners of male patients who are of childbearing age. 
Emotional status needed evaluation as depression was not uncommon and suicides were 
reported. 
 
Monitoring during treatment 
Haematology and chemistry: At weeks 1, 2, 4, 6  and 8 and then every 4 weeks. 
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TSH, FT4: Every 12 weeks. 
Pregnancy test: Every 4 weeks. 
Two effective modes of contraception (barrier method + other) must be used for the entire 
duration of therapy. 
Patients receiving Peg-IFN/RBV had a quantitative HCV-RNA test at 12 weeks. 
Individuals who had a detectable HCV-RNA > 50 IU/mL (i.e have not obtained early 
virological response)  or a drop in viral load <2 log10, are unlikely to achieve SVR and 
treatment may be stopped. Patients with cirrhosis potentially benefited from continued 
treatment and the decision to stop depended on the assessment by the physician on an 
individual basis. 
 
Investigations 8 weeks after COT: 
Haematology: FBC 
Chemistry: ALT 
Investigations 24 weeks after COT: 
Haematology: FBC 
Chemistry: ALT 
HCV-RNA (qualitative). Failure to detect HCV-RNA at this point is considered SVR or 
cure. 
 
DIRECT-ACTING ANTIVIRAL THERAPIES  
 
Table 1 lists the different directly acting antivirals and their sites of action. 
 
DAAs directly inhibit viral replication by targeting essential viral proteins. Four main 
classes have been developed which inhibit three viral proteins: NS3/4A protease 
inhibitors, NS5A inhibitors and two types of NS5B polymerase inhibitors. The ‘first-wave’ 
of DAAs was approved in 2011 for the treatment of HCV genotype 1 infection. The first 
protease inhibitors were the NS3/4A inhibitors, Telaprevir (TVR) and Boceprevir (BOC) 
that  were administered in combination with Peg-IFN/RBV as triple therapy. SVR rates 
improved from 40% with interferon-based regimens, to 70-80% using the triple therapy 
with BOC or TVR and shortened treatment duration. (46-48). Adverse effects were still 
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considerable and often resulted in therapy intolerability and treatment cessation. In 2013, 
a second generation protease inhibitor, Simeprevir was approved and achieved SVR 
rates between 75 and 86% in genotype 1 infected patients with slightly higher rates in 
patients treated with higher doses and longer duration of therapy. (49) Antiviral activity 
was also demonstrated in all other HCV genotypes, except genotype 3. (50)  
 
In the same year, an NS5B polymerase inhibitor, Sofosbuvir (SOF) was administered as 
triple therapy alongside PegIFN/RBV. It has pan-genotypic antiviral activity, is well 
tolerated and genotype 2 and genotype 4 patients achieved high rates of SVR. While 
rates of SVR in genotype 3 were lower, outcomes were improved with longer duration of 
treatment. (51) 
 
Interferon-free therapies that combine two or more DAAs have improved tolerability and 
efficacy. Two or more DAA classes are used with or without RBV in order to increase the 
barrier to resistance. Phase 3 trials of daclatasvir (DCV) plus asunaprevir (ASN), 
ombitasvir (OBV) plus paritaprevir (PTV)/RBV and sofosbuvir plus ledipasvir (LDV) have 
shown fewer side-effects and improved SVR rates. (52) ASN plus DCV was the first 
interferon-free DAA therapy achieving SVR rates of 78% when used alone and 95% when 
used in combination with PegIFN/RBV, to treat patients with genotype 1 infection. (53) 
 
DCV plus ASN therapy (54) and SOF plus LDV, (55) have been approved for treatment 
of genotype 1 infection, and SOF plus RBV has been approved for genotype 2 infection. 
(56) 
 
The combination of SOF and LDV is recommended for genotype 1 and genotype 4-6 
infection, with phase 3 trials showing SVR rates between 94% and 99% in genotype 1 
patients. (57)  
 
PTV/ritonavir (RTV), OBV, and dasabuvir (DSV), with or without RBV is an alternative to 
SOF/LDV and ASN/DCV therapies. (52) A second generation protease inhibitor 
grazoprevir (GZR) demonstrates pan-genotypic antiviral activity. Treatment-naïve 
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genotype 1 patients were treated with a combination of GZR and elbasvir (EBR) and 
achieved a 93% SVR rate. (58)  
 
A RBV-free combination of SOF and Simeprevir (SMV) has been shown to be effective 
in treating genotype 1 and genotype 4 infection. SVR rates of 97% were achieved in 
patients with genotype 1 infection without cirrhosis and 83% in patients with cirrhosis. (59) 
 
The combination of SOF and DCV with or without RBV is effective in genotype 1, 2 and 
3 achieving SVR rate of 98%, 92% and 89%, respectively. (60) 
 
In 2016, the FDA approved the first fixed-dose combination pan-genotypic regimen. The 
RBV-free SOF and velpatasvir (VEL) has been shown to be an effective pan-genotypic 
therapy. In a phase 3 trial, patients achieved SVR rates of 98%, 100%, 100%, 97%, and 
100% for genotype 1, 2, 4, 5 and 6, respectively. (61) 
 
Glecaprevir and Pibrentasvir is a fixed-dose combination regimen of a new generation 
NS3/4A inhibitor and NS5A inhibitor with potent pan-genotypic antiviral activity. This 
combination has a high barrier to resistance and in 3 phase 3 studies produced SVR rates 
of 93% in patients without cirrhosis infected with genotype 2, 4, 5 and 6. (62) In another 
phase 3 trial, the combination of glecaprevir and pibrentasvir resulted in high rates of SVR 
among patients without cirrhosis who had genotype 1 infection (>99%) and genotype 3 
infection (95%). A treatment duration of 8 weeks yielded non-inferior SVR rates when 
compared to 12 weeks of therapy. (63) 
 
CONCLUSION 
In order to achieve the WHO goal of viral hepatitis elimination by 2030, there is a need 
for accurate global epidemiological data, identification of HCV-infected individuals and 
linkage to care. The lack of data with regards to defined cohorts in South Africa needs to 
be addressed. This study documented our local experience with regards to the burden of 
disease, patient demographics and treatment outcomes with Interferon-based therapy. 
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Table 1. Direct acting antivirals and sites of action  
Protease inhibitor   
NS3/4A inhibitor  NS5A inhibitor NS5B inhibitor 
Telaprevir 
Boceprevir 
Simeprevir 
Grazoprevir 
Paritaprevir 
Asunaprevir 
Voxileprevir 
Glecaprevir 
Daclatasvir 
Ledipasvir 
Elbasvir 
Ombitasvir 
Velpatasvir 
Odalasvir 
Sofosbuvir 
Dasabuvir 
Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, et al. Hepatitis 
C treatment: Where are we now? Int J Gen Med. 2017;10:39-52. 
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ABSTRACT 
 
Background 
Hepatitis C (HCV) in South Africa is incompletely characterised and understood. Epidemiological 
and clinical data will better inform our understanding and assist national policy decision making. 
On the background of more than two decades of clinical challenges in HCV management, the 
advent of direct-acting antivirals (DAA) now makes HCV elimination plausible. To better 
understand the base from which we come, we elected to review and characterise our HCV 
experience at Groote Schuur Hospital (GSH) in the pegylated interferon (Peg-IFN) and ribavirin 
(RBV) management era. 
 
Methods 
Patients with chronic HCV attending GSH Liver Clinic from 2002 to 2014, were included in the 
analysis. Relevant data were extracted from a registry and existing clinical records accessed. Two 
brands of Peg-IFN were available and those treated with the first generation add-on protease 
inhibitor, telaprevir, were included. 
  
Results 
238 patients were included in the analysis, median age of 47 (IQR 37-58) years, men 60.5%.  Men 
were significantly younger than women, 43.5 (35-52) vs 55 (42-64) years, respectively, p<0.0001. 
Ethnically, the majority were white (55.9%) or mixed-ancestry (21.8%), 16.4% were HIV co-
infected, 3.7% hepatitis B (HBV) co-infected and 0.4% triple infected with HCV, HBV and HIV. 
The most likely mode of HCV acquisition was blood or blood product exposure prior to 1992 
(32.8%) and injecting drug use (IDU) 17.6%, while 30.3%, had no clear risk factor identifiable. 
Genotypes (GT) 1 to 5 were observed with GT-1 (34.9%) predominating. In those biopsied, 
(n=90), 30% ≥F3 fibrosis, with 15.6% cirrhotic. With IL28B polymorphisms, heterozygous CT 
(23.9%) and CC genotype (15.5%), were most frequent. 32.6% accessed Peg-IFN/Ribavirin-based 
therapy, 6.5% (n=5) with add-on telaprevir. GT-1 (35.1%) was most prevalent in the treatment 
group, followed by GT-3 (26%) and GT-5 (18.2%); 10% were HIV co-infected. Overall SVR rate 
was 75.3% with 37% of GT-1 not achieving SVR; 49.4% experienced adverse events including 
cytopenias (32.5%) and depression (15.6%). A total of 23.4% of patients required cell support in 
the form of erythropoietin and/or GM-CSF.  
  
Conclusion 
HCV patients in the Peg-IFN/Ribavirin management era typified the epidemiology of HCV.  GT 
distribution was pangenotypic and treatment outcomes were encouraging despite treatment 
challenges. Patient selection, IL28B and sensible cytopenias support, likely accounted for this. 
However numbers treated were limited and the DAA era of therapy allows for a rapid expansion 
of therapy with now growing numbers of patients and a changing local epidemiology.  
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Introduction 
 
In 2016 World Health Assembly of the World Health Organisation (WHO) approved the first 
Global Health Sector Strategy to eliminate viral hepatitis. The aim of the strategy is to eliminate 
viral hepatitis by 2030, and was defined as a 90% reduction in the incidence of new infections with 
a consequent 65% reduction in mortality from associated liver disease.(1) Globally, hepatitis C 
virus (HCV) prevalence is 1% equating to an estimated 71.1 million people with active hepatitis 
C viremia resulting in HCV being a leading cause of chronic liver disease. The global burden of 
liver disease continues to increase due to hepatitis C related cirrhosis, hepatocellular carcinoma, 
liver failure and death.(2) The epidemiology and prevalence of chronic HCV in South Africa (SA), 
remains poorly characterised and understood. Few data exists in defined cohorts of patients with 
chronic HCV and responses to therapy. The modelled prevalence of HCV viremia in SA, as of 
2015, is between 0.4 and 0.9 %, with genotype 1b (22.1%) thought to be most frequent, although 
genotypes 1 to 5 are prevalent.(2) 
 
Following the identification and sequencing of HCV in 1989 by Choo and colleagues,(3) the 
management of chronic HCV infection has undergone a revolution. Initially, treatment with 
standard interferon yielded poor response rates.(4)  Consequently, pegylated interferon and oral 
ribavirin (Peg-IFN/RBV) enhanced response with sustained virological response (SVR) rates of ~ 
50%.(5)  Despite improved SVR rates, treatment was costly and associated with significant adverse 
effects that resulted in patients discontinuing therapy. Cytopenias associated with drug toxicities 
sometimes necessitated erythropoietin (EPO) and/or granulocyte macrophage colony-stimulating 
factor (GM-CSF) to support treatment sustainability.(5) Factors influencing a positive treatment 
outcome included the ability to complete >80% of the planned duration of treatment with >80% 
of the required doses of Peg-IFN and ribavirin,(6) the IL28B polymorphism genotype, the baseline 
viral load, degree of liver fibrosis and genotype. In 2012, the first of a new generation of add-on 
oral protease inhibitors, specifically for genotype 1 HCV, emerged.  These drugs, telaprevir and 
boceprevir, significantly improved SVR rates but at the expense of enhanced adverse effects.(7-9) 
The advent of the all oral direct-acting antivirals (DAA) for hepatitis C has revolutionised therapy 
with SVR response rates now exceeding 95% with fewer adverse effects. The success of DAA 
therapy has made HCV elimination now very plausible.  
 
The initial availability of Peg-IFN/RBV in South Africa emerged in 2002, and by 2004, the 
University of Cape Town/Groote Schuur Hospital (UCT/GSH) Liver Clinic was able to access this 
standard of care for HCV-infected individuals via several mechanisms including compassionate 
use or expanded access treatment programmes, a hospital allocated budget to treat a limited 
number of HCV-infected individuals annually or private funding. Given the advent of the DAA 
era of treatment, we elected to review and describe our experience with interferon-based therapy 
over a decade plus period from 2002 to 2014. We document our local experience with regards to 
the patient demographics; clinical, biochemical and genetic profile of the study population; viral 
characteristics, and treatment outcomes (side-effect profile and SVR rates) with interferon-based 
therapy during this period. No such data exists for South Africa, and reviewing our experience 
serves as a benchmark to compare the rapidly expanding, albeit currently limited, DAA era of 
HCV treatment in South Africa. This study hence serves to inform national policy decision making 
structures of the base from which we have functioned with respect to hepatitis C in South Africa. 
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Given the need for data in informing such policy, this study aims to support such policy structures 
in achieving South Africa’s efforts for viral hepatitis elimination by 2030. 
Methods 
All patients with hepatitis C virus infection attending the UCT/GSH Liver Clinic from 2002 up to 
and including 2014, were included. All relevant patient demographic data and clinical 
characteristics were extracted from a patient registry, in addition to existing clinical records, and 
recorded in a database. In terms of treatment, 2 brands of Peg-IFN viz. Pegylated Interferon α-2b 
(Peg-IntronR, Schering-Plough) and Pegylated Interferon α-2a (PegasysR, Hoffman-La Roche) 
were available in South Africa during the study period and patients using either product, were 
included. Standard Peg-IFN/RBV treatment guidelines based on genotype were followed. Patients 
treated with the addition of the first generation DAA therapy (Telaprevir) to their Peg-IFN/RBV 
regimen, were also included in the final analysis.   
 
Laboratory tests 
All baseline biochemistry, full blood count and INR were recorded. Human Immunodeficiency 
Virus (HIV) status was confirmed by ELISA testing for HIV antibody and p24 antigen and in those 
HIV co-infected, CD4 count (cells/mm3) was recorded at the time of presentation. Viral serological 
testing (ARCHITECT I or II, Abbott Diagnostics) for hepatitis C (Hepatitis C IgG-antibody) was 
positive in all participants and active viremia confirmed by an in-house PCR technique amplifying 
the 5’NCR region of HCV. Genotype was determined using the Versant HCV Genotype v2.0 Line 
Probe Assay (Siemens AG) or through in-house NS5B sequencing. HCV viral loads were 
measured using the COBAS Ampliprep/Cobas TaqMan v2.0 (Roche Diagnostics). Serological 
testing for hepatitis A (Hepatitis A IgG antibody) and hepatitis B (HBsAg, HBcore IgG and core 
IgM-antibody) was performed. 
Liver biopsy was used to assess fibrosis unless contraindicated (e.g. in hemophiliacs or 
coagulopathic patients). Liver biopsies were all assessed by one of two experienced liver 
histopathologists while clinicopathologic assessments were done concurrently with hepatologists. 
Hepatitis C was staged and graded using the METAVIR system.    
 
Ethics approval 
This study was approved by the University of Cape Town Human Research Ethics Committee 
(HREC REF: R045/2014). 
 
Statistical analysis  
Values are expressed as the median and interquartile range (IQR) for continuous variables. Clinical 
characteristics were summarised using standard descriptive characteristics. Where appropriate, 
differences between qualitative parameters were explored using the Wilcoxon Rank sum test.  
Statistical analysis was performed using Microsoft Excel (2013). 
 
Results 
Included in the evaluation of the total cohort was n=238 patients, the majority male, 60.5% (n=144) 
(see Table 1). The median age (IQR) of the cohort was 47 (37-58) years, however men were 
significantly younger than women, 43.5 (35-52) vs 55 (42-64) years, respectively, p<0.0001. Of 
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note, demographically and self-identified heterosexual male patients were significantly older than 
men who have sex with men (MSM), 49 (47-51) vs. 40.5 (34-45) years, respectively, p=0.0002.  
Ethnically, the majority of patients were white (55.9%), followed by mixed-ancestry (21.8%) and 
black Africans (13.9%). The likely mode of HCV acquisition was predominantly blood or blood 
product exposure prior to 1992 (32.8%), parenteral through injecting drug use (IDU) 17.6% or 
through parenteral or percutaneous exposure (10.9%) e.g. needle stick injuries, tattoos, etc.  
Hemophiliacs comprised 13.4% of patients. No clear route could be identified in almost a third 
(30.3%) of patients. In terms of genotype (GT) distribution (table 2), GT-1 (34.9%) predominated 
with GT-1a more prevalent than 1b, 62.7% vs. 36.3%, respectively. Genotypes 3, 4 and 5 were 
present in almost similar frequencies (18.1%, 17.2%, and 16% respectively) with GT-2 (6.7%) 
least frequent. Genotype was not identified in 7.1% of the cohort. Virologically, the median 
hepatitis C viral load was 5.6 (4.7-6.2) log10 IU/ml. In addition, 16.4% were HIV co-infected with 
a median baseline CD4 count of 395 cells/mm3. In terms of HBsAg, 3.7% (n=8) were hepatitis B 
co-infected and 1 patient (0.4%) was triple infected with HIV, HBV and HCV. In those screened 
for hepatitis A immunity (anti-HAV IgG), 71.5% were positive.  
Baseline laboratory characteristics are shown in Table 3 demonstrating that median baseline 
alanine transaminase (ALT) and aspartate transaminase (AST), were elevated, however 29.8% 
(n=71) had an ALT within the laboratory “normal” range. In Table 4, the biopsy features are listed 
(n=90).  In terms of the METAVIR score, 30% had ≥F3 fibrosis, with 15.6% cirrhotic. Most had 
F2 fibrosis. Ancillary biopsy data demonstrated a high frequency of steatosis (63.3%) and iron 
overload present in 12.2%.  
Table 5 notes all ancillary clinical or laboratory data. From 2011, all patients were screened for 
the IL28B allele. The heterozygous IL28B CT allele was most frequent followed by the 
homozygous CC or TT alleles. Homozygosity or heterozygosity for the HFE C282Y or H63D 
alleles are highlighted, with homozygosity infrequently observed. Diabetes mellitus was highly 
prevalent (17.6%). Although alcohol consumption was not accurately assessed, 16.4% of patients 
confirmed regular consumption.  
Only 32.3% (n=77) of HCV-infected patients accessed Peg-IFN/RBV-based therapy (Table 6). 
Five patients received add-on first generation protease inhibitor treatment, viz.Telaprevir. These 5 
patients were all GT-1, of whom 2 patients had previously failed treatment. Genotype distribution 
in the treatment group comprised GT-1 (35.1%), GT-2 (11.7%), GT-3 (26%), GT-4 (9.1%) and 
GT-5 (18.2%). Eight treated patients (10%) were HIV co-infected, and one triple infected. Most 
patients (71.5%) treated were ≥F2 fibrosis, with 28.6% ≥F3 and 14.3% compensated cirrhotics. 
Overall SVR was 75.3% with more than half (55.8%) achieving a rapid virological response 
(RVR) and 84.4% achieving an early virological response (EVR). Of the 19 patients not achieving 
an SVR, the majority (52.6%) were GT-1. All GT-2 patients achieved SVR. In patients tested for 
IL28B prior to treatment, 77%, 66% and 40% of the CC, CT and TT genotype, respectively, 
achieved a SVR. The median HCV viral load (log copies/ml) did not differ between those who did 
and did not achieve SVR, 5.85 (IQR 5.0-6.4), 5.8 (IQR 5.45-6.45), respectively, p=0.56. 
Table 7 demonstrates the event rate of adverse effects related to Peg-IFN/RBV therapy with 49.4% 
of patients experiencing adverse effects. Surprisingly only a single patient discontinued therapy 
because of adverse effects. The need for cytopenia support was substantial with 7.8% and 7.8% of 
patients, respectively, requiring EPO for anaemia to maintain ribavirin dose or GM-CSF support 
to maintain Peg-IFN dose for treatment-related neutropenia. An equal number of patients required 
a combination of EPO and GM-CSF (7.8%).  Psychiatric side effects, especially depression, 
presented in 15.6% of patients.  
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Discussion 
There are several observations consistent with typical patterns of HCV epidemiology in our Liver 
Clinic cohort during the time period 2002 to 2014. Data now supports that 2 distinct 
epidemiological patterns of infection exist that creates a bimodal age distribution for chronic 
hepatitis C.(10) The first group are older and likely acquired infection through a variety of 
mechanisms including blood or blood product exposure pre-1992, injecting drug use (IDU) and 
other parenteral modes of infection. This is clearly reflected in our cohort with one-third having 
blood or blood product exposure prior to 1992. Less represented are recent or current injecting 
drug users, given their lower likelihood to have presented or be referred for therapy given the 
rigours of Peg-IFN/Ribavirin-based therapy. Current transmission, in younger patients, is driven 
predominantly by people who inject drugs (PWID) and MSM, especially if HIV-infected.(11) In 
our study, men were younger than women, and MSM were significantly younger than non-MSM 
patients. This is consistent with this pattern of HCV infection. In addition, we have previously 
documented high rates of HCV infection in HIV-positive MSM in Cape Town, South Africa.(12-14) 
Globally genotypes 1 and 3 predominate, responsible for 44% and 25% respectively, of global 
HCV infection.(2) In a recent South African study of HCV characteristics in blood donors and the 
general population for the period 2008 to 2011, genotype 1 was observed in 34%, with genotype 
5a being most prevalent (36%).  GT-5a accounted for 54% of infections in black South Africans 
with genotype 1 seen in 43% of white South Africans. Genotypes 3 and 4 occurred at the same 
frequency (14% respectively) and least frequent was genotype 2.(11-16)    The genotype distribution 
in our patient cohort was somewhat similar, except for GT-5a. This is not unexpected given the 
generally higher prevalence of GT-5a in the northern half of South Africa. GT-1 is invariably more 
prevalent in the Southern portion of the country. Similarly, GT-4 was more prevalent compared to 
HCV genotype distribution studies of the 1990s.(17) This likely reflects patterns of immigration 
into South Africa over the past 2 to 3 decades by people from GT-4 predominant parts of Africa. 
The GT-4 subtype variation also supports this notion.  Furthermore, our study again reinforces the 
HCV pangenotypic status (GT 1 to 5) of South Africa, which has implications for elimination 
programmes based on DAA therapy in the future.   
In terms of the mode of HCV acquisition, IDU and blood or blood product exposure dominated. 
This is unsurprising, however in a considerable proportion of patients, no clear mode was 
identifiable. Factors such as traditional or unsafe medical practices likely account for these 
patients’ hepatitis C. This creates substantial difficulty when making recommendations on 
population screening for hepatitis C in South Africa as part of a national elimination strategy.   
The median ALT, as anticipated, was elevated however the cohort demonstrates the well 
recognised phenomenon of a laboratory “normal” ALT value in a substantial component, 29.8%, 
of participants. This is well recognised in patients with chronic hepatitis C where typically one-
quarter of patients can have so-called normal transaminases.(18) This again underpins the reason as 
to why ALT should not be used and is a poor surrogate marker for active hepatitis C viremia.  
In the time period under review, only a third of patients accessed Peg-IFN/Ribavirin-based therapy.  
This is not unexpected given several reasons including the limited funding available to treat 
patients, the significant cost of Peg-IFN/Ribavirin treatment, the adverse effects of treatment and 
contraindications to treatment. In addition, patients with difficult to treat HCV genotypes or HIV 
co-infection with minimal fibrosis, were warehoused in anticipation of more effective therapies 
with fewer side effects. Despite this, the number of patients treated was substantial and represents 
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the single largest reported cohort of patients treated with Peg-IFN/RBV-based hepatitis C therapy 
in South Africa to date. Given that almost two-thirds of patients treated were the more difficult 
genotype 1, 4 or 5 (35.1% GT-1 alone), almost one-third with advanced fibrosis and 10% HIV co-
infected, treatment outcomes in terms of SVR at 75.3% of  patients, were very good. Given that 
SVR rates in most large cohort studies ranged between 54% and 66%, our outcomes were 
particularly encouraging and several reasons likely accounted for this. Firstly, patient selection is 
important in terms of those more motivated for treatment, more favourable IL28B genotypes and 
the judicious use of supportive therapy to allow for maximum dose of Peg-IFN and ribavirin to be 
used. In terms of patient selection, those with liver biopsies demonstrating more necro-
inflammatory activity and greater degrees of fibrosis, were more likely to be offered therapy.   
Looking at the IL28B single nucleotide polymorphism, of those tested, most patients had the more 
favourable IL28B CC or CT genotype as opposed to the less favourable TT genotype.  Data from 
the large IDEAL study, was the first to demonstrate the significant predictive value of the relevant 
IL28B genotype in increasing the odds ratio in favour of a SVR. The IL28B CC genotype resulted 
in an odds ratio that increased the likelihood of SVR 3 to 7 times in those with the CC 
polymorphism genotype.(19)  In keeping with this, in our study 77% and 66%, respectively of the 
CC and CT genotype patients, achieved an SVR as compared to 40% of the TT genotype 
participants.  
Treatment outcomes are influenced by on treatment factors such as achieving an RVR and the 
ability to maintain maximum doses of Peg-IFN and ribavirin. Given the cytopenic side effects of 
Peg-IFN/RBV, the use of GM-CSF to maintain absolute neutrophil counts and EPO to maintain 
haemoglobin levels, is crucial to allow for continued regular administration of Peg-IFN/RBV at 
recommended doses.(5)  In our treated patients, almost a quarter of patients (23.4%) received GM-
CSF and/or EPO support to allow for continued dosing of Peg-IFN/RBV, respectively. This 
enabled patients to complete the required duration of therapy while tolerating maximal doses and 
likely contributed to the SVR rates achieved in our cohort. Maintaining Peg-IFN and ribavirin 
dosing at ≥80% has a positive effect on SVR likelihood(6) 
Adverse events, as anticipated, were frequent.  Rates of psychiatric adverse events, typically 
depression, were reported to occur in 5 – 20%.(20, 21) Just over 15% of our patients were diagnosed 
with depression that required an intervention either with an antidepressant and/or counselling and 
support. The rates of adverse events in our treated patient cohort support the difficulties of Peg-
IFN/RBV-based therapy. Adverse effects tend to occur within first 12 weeks so whilst duration is 
affected, need for support was no different between the 2 groups viz. 24/48 weeks. We were 
fortunate in that only 1 patient discontinued therapy because of adverse events.  Adverse effects 
were compounded in those patients using the add-on protease inhibitor therapy, telaprevir. Whilst 
numbers were small, 80% of GT-1 patients using telaprevir in conjunction with Peg-IFN/RBV, 
achieved SVR.   
With regards to study limitations, this is a retrospective study and not all required data was 
available. IL28B genotyping only became available in 2011. Resource constraints resulted in a 
limited number of patients being treated and very careful selection was required to ensure that 
those treated had the greatest likelihood of cure. This selection bias may have inflated SVR rates. 
There may be underrepresentation of certain high risk populations such as IDU, because of them 
being less likely to present or be referred. 
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Conclusion 
The HCV patient population in the Peg-IFN/RBV era in the clinic represented the more typical 
epidemiology of HCV acquisition either via previous IDU or blood transfusion prior to 1992.   
Notably we are pangenotypic in GT distribution and our treatment outcomes during this era were 
commendable despite significant treatment challenges and adverse events. Careful patient 
selection, favourable IL28B alleles and sensible cytopenia support as well as on-treatment 
responses with high rates of RVR and EVR, likely account for this. Our study is the first of its kind 
documenting outcomes with Interferon-based therapy for hepatitis C in South Africa. It will serve 
as a benchmark for comparison with the performance of DAAs in South Africa. Given the need 
for data in informing national policy decision making structures and the fact that no such data 
exists, this study serves to inform and support such policy structures, and encourage government 
to provide the economic infrastructure required to support South Africa’s effort for viral hepatitis 
elimination by 2030, of which DAA therapy for hepatitis C, will be the foundation of management.  
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Table 1. Demographic characteristics of the study population. 
Parameter 
 
N=238 P-value 
Male, n (%) 
Heterosexual* 
MSM* 
 144 (60.5) 
 112 (47.1) 
   32 (13.4) 
 
 
Age† distribution, median (IQR) 
   Total cohort 
   Male: female 
   Heterosexual: MSM 
 
   47 (37-58) 
43.5 (35-52) : 55    (42-64) 
   49 (47-51) : 40.5 (34-45) 
 
 
 
0.0001 
0.0002 
Ethnicity‡, n (%) 
   Asian  
   Black  
   Mixed ancestry  
   White  
 
 
   20 (  8.4) 
   33 (13.9) 
   52 (21.8) 
 133 (55.9) 
 
 
Mode of acquisition, n (%) 
   Transfusions§ 
   Unknown 
   Injection drug use 
   Parenteral/percutaneous 
   Unsafe medical procedures⁋ 
   Sexual encounter 
   Perinatal Mother to Child 
 
   78 (32.8) 
   72 (30.3) 
   42 (17.6) 
   26 (10.9)    
   13 (  5.5) 
     5 (  2.1) 
     2 (  0.8) 
  
 
Hemophiliac, n (%)  
   Total  
    
 
   32 (13.4)    
 
The data is expressed as medians and interquartile ranges (IQR) or numbers and percentages                                             
Abbreviations: MSM = men who have sex with men 
* Sexual orientation is self-reported 
† Age (years) at presentation 
‡ Ethnicity is self-reported 
§ Blood and blood products, including hemophiliacs 
⁋ Surgical/dental/orthodontic procedures 
 
 
 
 
 
 
 
49 | P a g e  
 
Table 2. Viral and baseline laboratory characteristics 
 
HCV viral load (log10IU/ml, median, IQR) 
   N = 238 
5.6 (4.7 - 6.2)  
 
   Genotype, n (%) 
              GT-1 
              GT-2 
              GT-3 
              GT-4 
              GT-5 
      Not tested 
 
 
   83 (34.9) 
   16 (6.7) 
   43 (18.1) 
   41 (17.2) 
   38 (16.0) 
   17 (7.1)  
 
     Genotype Subtype 
             GT-1a  
             GT-1b 
             GT-2a 
             GT-2b 
             GT-3a 
             GT-3b 
             GT-4a 
             GT-4c 
             GT-4e 
             GT-5a 
       Not tested 
    N = 238 
   42 (17.6) 
   25 (10.5) 
     4 (  1.7) 
     4 (  1.7) 
   36 (15.1) 
     1 (  0.4) 
     2 (  0.8) 
     2 (  0.8) 
     5 (  2.1) 
   30 (12.6) 
   17 (  7.1) 
n*, (%) 
     42 (62.7) 
     25 (37.3) 
       4 (50) 
       4 (50) 
     36 (97.3) 
       1 (2.7) 
       2 (22.2) 
       2 (22.2) 
       5 (55.6) 
     30 (100) 
 
Serological markers 
Hepatitis A Virus 
 Anti-HAV IgG† (n=123) 
Hepatitis B Virus 
 HBsAg‡ (n=219) 
HIV§ (n=189) 
     Baseline CD4 count  (cells/mm3) 
HIV/HBV/HCV⁋ 
  
 
   88 (71.5) 
  
     8 (  3.7)    
   31 (16.4) 
 395 (272 – 650) 
     1 (  0.4) 
 
The data is expressed as medians and interquartile ranges (IQR) or numbers and percentages 
GT = genotype; n = no. of patients tested.  
*n = the total no. of individuals with a genotype subtype.  
% = percentage of the total no. of individuals subtyped within the genotype:  GT-1 (N=67), GT-2 (N=8), GT-3 
(N=37), GT-4 (N=9) and GT-5 (N=30) 
†Hepatitis A IgG antibodies (hepatitis A immunity) 
‡Hepatitis B surface antigen (HBV co-infection) 
§HIV = Human Immunodeficiency Virus 
⁋HIV/HBV/HCV = triple infected 
 
50 | P a g e  
 
Table 3. Baseline laboratory characteristics of the study population (N=238) 
Parameter  Ref range* Median (IQR) 
TBil(µmol/L) 
Alb (g/L) 
ALT (U/L) 
AST (U/L) 
INR 
Hb (g/dL) 
WCC (x109/L) 
Platelets (x 109/L) 
AFP (µg/L) 
Ferritin (µg/L) 
     0 - 21 
   35 - 52 
     5 - 40 
     5 - 40 
 
13.0 - 17.0 
  4.0 - 10.0 
 137 - 373 
  0.0 - 7.0 
   30 - 400 
   10 (7 – 16) 
   43 (38-47) 
   60 (35-109) 
   50 (32-89) 
     1 (0.9-1.1) 
14.4 (13.1-15.8) 
  6.2 (5-7.8) 
 225 (156-278) 
  3.9 (2.4 - 6.8) 
 189 (90-438) 
Abbreviations: TBil = Total bilirubin; Alb = Albumin; ALT = Alanine aminotransferase; AST = Aspartate 
aminotransferase; INR = International normalised ratio; Hb = Haemoglobin; WCC = White cell count; Plts = 
Platelets; AFP = Alpha fetoprotein  
*Laboratory reference range 
 
Table 4.  Liver biopsy results  
 
 
 
No. of biopsies performed, n (%)  
 
    
   N = 238 
   90  (37.8) 
 
 
 
Presence of steatosis, n (%) 
Presence of iron  
 
 
   N = 90  
   57  (63.3) 
  11  (12.2) 
Metavir activity score*  
     0 
     1 
     2 
     3 
     4 
 
 
    3  (3) 
  48  (53) 
  25  (28) 
  14  (16) 
    0  (0) 
Metavir fibrosis score†  
     0 
     1 
     2 
     3 
     4 
 
    9  (10) 
  15  (16.7) 
  39  (43.3) 
  13  (14.4) 
  14  (15.6) 
The data is expressed as numbers and percentages    
*Metavir activity score: 0=no active inflammation; 1=minimal inflammation; 2=moderate inflammation; 3=severe; 
4=very severe. 
†Metavir fibrosis score: 0=no fibrosis; 1=minimal fibrosis; 2=scarring fibrosis; 3=bridging fibrosis; 4=cirrhosis. 
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Table 5. Ancillary clinical and laboratory data, N=238 
 
 
Diabetes Mellitus, n (%)  
HBA1C (%), median (IQR)  
 
Hereditary Hemochromatosis (HFE genes), n (%)  
            C282Y heterozygous  
 C282Y homozygous  
 H63D heterozygous  
 H63D homozygous  
 Not tested  
 
Alcohol consumption*, n (%)    
 Yes  
 No  
 
IL28B Allele, n (%)    
 CC  
 CT   
 TT  
 Not tested  
 
 
 42  (17.6%) 
   7.7  (6.8 – 8.8) 
 
 
       
      
      5  (  2.1) 
      1  (  0.4) 
    19  (  8.0) 
      1  (  0.4) 
  147  (61.8) 
 
 
   39  (16.4) 
  199  (83.6) 
 
 
    37  (15.5) 
    57  (23.9) 
    18  (  7.6) 
  126  (52.9) 
 
The data is expressed as medians and interquartile ranges or numbers and percentages.                                         
*Self-reported 
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Table 6. PEG-IFN/RBV treated patients  
 
Genotype distribution  GT-1 GT-2 GT-3 GT-4 GT-5 
Total treated, n (%) (N=77) 
SVR* 
No SVR* 
 
27 (35.1) 
  17 (63) 
  10 (37) 
9 (11.7) 
9 (100) 
0 
   20 (26) 
   18 (90) 
  2 (10) 
7 (9.1) 
   4 (57) 
   3 (43) 
14 (18.2) 
10 (71.4) 
  4 (28.6) 
Liver biopsy results (N=49)      
   
        
Metavir activity score, n (%) 
0 
1 
2 
3 
4 
 
Metavir fibrosis score, n (%) 
0 
1 
2 
3 
4 
 
   1 (2) 
 31 (63.3) 
 11 (22.5) 
   6 (12.2) 
   0 (0) 
 
    
   5 (10.2) 
   9 (18.4) 
 21 (42.9) 
   7 (14.3) 
   7 (14.3) 
 
 
 
 
                    SVR†  
                    RVR‡   
                    EVR§   
         58 (75.3) 
  43 (55.8) 
  65 (84.4) 
        Treatment duration 
                 24 weeks 
                 48 weeks 
                 72 weeks 
 
38 (49.4) 
37  (48.1) 
  4  (  5.2) 
Abbreviations: GT = genotype 
*N = no. of patients treated in a specific GT subtype. 
†SVR = Sustained virological response is defined as an undetectable HCV-RNA 24 weeks after the end of 
treatment. 
‡RVR = Rapid virological response is defined as an undetectable HCV-RNA at 4 weeks of treatment. 
§EVR = Early virological response is defined as an undetectable HCV-RNA or > 2 log reduction of HCV-RNA at 
12 weeks of treatment. 
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Table 7. Treatment adverse effects (N=77) 
 
Patients who experienced adverse effects 
Patients stopping therapy because of adverse effects 
 
Side-effects experienced 
    Neutropenia 
    Anaemia 
    Thrombocytopenia 
    Bicytopenia 
    Pancytopenia 
    Psychiatric 
    Psychiatric and cytopenia 
    Rash 
 
38 (49.4) 
  1 (1.3) 
 
 
10 (11.7) 
  4 (5.2) 
  4 (5.2) 
  3 (3.9) 
  4 (5.2) 
  7 (9.1) 
  5 (6.5) 
  1 (2.6) 
 
Cell Support Required (N=18) 
    No. of patients requiring EPO  
    No. of patients requiring GM-CSF  
    No. of patients requiring EPO and GM-CSF 
 
 
6 (7.8%) 
6 (7.8%) 
6 (7.8%) 
EPO = erythropoietin; GM-CSF = Growth-Colony Stimulating Factor 
 
 
 
 
 
 
 
 
 
 
 
54 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3: APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55 | P a g e  
 
APPENDIX 1: South African Medical Journal - Instructions to Authors 
Research  
Guideline word limit: 4 000 words 
 Research articles describe the background, methods, results and conclusions of an 
original research study. The article should contain the following sections: introduction, 
methods, results, discussion and conclusion, and should include a structured abstract 
(see below). The introduction should be concise – no more than three paragraphs – on 
the background to the research question, and must include references to other 
relevant published studies that clearly lay out the rationale for conducting the study. 
Some common reasons for conducting a study are: to fill a gap in the literature, a 
logical extension of previous work, or to answer an important clinical question. If other 
papers related to the same study have been published previously, please make sure to 
refer to them specifically. Describe the study methods in as much detail as possible so 
that others would be able to replicate the study should they need to. Results should 
describe the study sample as well as the findings from the study itself, but all 
interpretation of findings must be kept in the discussion section, which should consider 
primary outcomes first before any secondary or tertiary findings or post-hoc analyses. 
The conclusion should briefly summarise the main message of the paper and provide 
recommendations for further study. Select figures and tables for your paper carefully 
and sparingly. Use only those figures that provided added value to the paper, over and 
above what is written in the text. 
Do not replicate data in tables and in text. 
Structured abstract 
 This should be 250-400 words, with the following recommended headings: 
o Background: why the study is being done and how it relates to other published work. 
o Objectives: what the study intends to find out 
o Methods: must include study design, number of participants, description of the 
intervention, primary and secondary outcomes, any specific analyses that were done on 
the data. 
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o Results: first sentence must be brief population and sample description; outline the 
results according to the methods described. Primary outcomes must be described first, 
even if they are not the most significant findings of the study. 
o Conclusion: must be supported by the data, include recommendations for further 
study/actions. 
 Please ensure that the structured abstract is complete, accurate and clear and has 
been approved by all authors. 
 Do not include any references in the abstracts. 
Main article 
All articles are to include the following main sections: Introduction/Background, 
Methods, Results, Discussion, Conclusions. 
The following are additional heading or section options that may appear within these: 
 Objectives (within Introduction/Background): a clear statement of the main aim of the 
study and the major hypothesis tested or research question posed 
 Design (within Methods): including factors such as prospective, randomisation, blinding, 
placebo control, case control, crossover, criterion standards for diagnostic tests, etc. 
 Setting (within Methods): level of care, e.g. primary, secondary, number of participating 
centres. 
 Participants (instead of patients or subjects; within Methods): numbers entering and 
completing the study, sex, age and any other biological, behavioural, social or cultural 
factors (e.g. smoking status, socioeconomic group, educational attainment, co-existing 
disease indicators, etc)that may have an impact on the study results. Clearly define how 
participants were enrolled, and describe selection and exclusion criteria. 
 Interventions (within Methods): what, how, when and for how long. Typically for 
randomised controlled trials, crossover trials, and before and after studies. 
 Main outcome measures (within Methods): those as planned in the protocol, and those 
ultimately measured. Explain differences, if any. 
 Results 
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 Start with description of the population and sample. Include key characteristics of 
comparison groups. 
 Main results with (for quantitative studies) 95% confidence intervals and, where 
appropriate, the exact level of statistical significance and the number need to 
treat/harm. Whenever possible, state absolute rather than relative risks. 
 Do not replicate data in tables and in text. 
 If presenting mean and standard deviations, specify this clearly. Our house style is to 
present this as follows: 
 E.g.: The mean (SD) birth weight was 2 500 (1 210) g. Do not use the ± symbol for 
mean (SD). 
 Leave interpretation to the Discussion section. The Results section should just report 
the findings as per the Methods section. 
 Discussion 
Please ensure that the discussion is concise and follows this overall structure – sub-
headings are not needed: 
 Statement of principal findings 
 Strengths and weaknesses of the study 
 Contribution to the body of knowledge 
 Strengths and weaknesses in relation to other studies 
 The meaning of the study – e.g. what this study means to clinicians and policymakers 
 Unanswered questions and recommendations for future research 
 Conclusions 
This may be the only section readers look at, therefore write it carefully. Include 
primary conclusions and their implications, suggesting areas for further research if 
appropriate. Do not go beyond the data in the article. 
Illustrations/photos/scans 
If illustrations submitted have been published elsewhere, the author(s) should provide 
consent to republication obtained from the copyright holder. 
 Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'. 
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 Each figure must have a caption/legend: Fig. 1. Description (any abbreviations in full). 
 All images must be of high enough resolution/quality for print. 
 All illustrations (graphs, diagrams, charts, etc.) must be in PDF or jpeg form. 
 Ensure all graph axes are labelled appropriately, with a heading/description and units 
(as necessary) indicated. Do not include decimal places if not necessary e.g. 0; 1.0; 2.0; 
3.0; 4.0 etc. 
 Scans/photos showing a specific feature e.g. Intermediate magnification micrograph of 
a low malignant potential (LMP) mucinous ovarian tumour. (H&E stain). –include an 
arrow to show the tumour. 
 Each image must be attached individually as a 'supplementary file' upon submission 
(not solely embedded in the accompanying manuscript) and named Fig. 1, Fig. 2, etc. 
 Tables 
 Tables should be constructed carefully and simply for intelligible data representation. 
Unnecessarily complicated tables are strongly discouraged. 
 Large tables will generally not be accepted for publication in their entirety. Please 
consider shortening and using the text to highlight specific important sections, or offer a 
large table as an addendum to the publication, but available in full on request from the 
author 
 Embed/include each table in the manuscript Word file - do not provide separately as 
supplementary files. 
 Number each table in Arabic numerals (Table 1, Table 2, etc.) and refer to 
consecutively in the text. 
 Tables must be cell-based (i.e. not constructed with text boxes or tabs) and editable. 
 Ensure each table has a concise title and column headings, and include units where 
necessary. 
 Footnotes must be indicated with consecutive use of the following symbols: * † ‡ § ¶ || 
then ** †† ‡‡ etc. 
 Do not: Use [Enter] within a row to make ‘new rows’: 
 Rather: 
Each row of data must have its own proper row: 
 Do not: use separate columns for n and %: 
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 Rather: 
Combine into one column, n (%): 
 Do not: have overlapping categories, e.g.: 
 Rather: 
Use <> symbols or numbers that don’t overlap: 
   
References 
NB: Only complete, correctly formatted reference lists in Vancouver style will be 
accepted. Reference lists must be generated manually and not with the use of 
reference manager software. Endnotes must not be used. 
 Authors must verify references from original sources. 
 Citations should be inserted in the text as superscript numbers between square 
brackets, e.g. These regulations are endorsed by the World Health Organization,[2] and 
others.[3,4-6] 
 All references should be listed at the end of the article in numerical order of appearance 
in the Vancouver style (not alphabetical order). 
 Approved abbreviations of journal titles must be used; see the List of Journals in Index 
Medicus. 
 Names and initials of all authors should be given; if there are more than six authors, the 
first three names should be given followed by et al. 
 Volume and issue numbers should be given. 
 First and last page, in full, should be given e.g.: 1215-1217 not 1215-17. 
 Wherever possible, references must be accompanied by a digital object identifier (DOI) 
link). Authors are encouraged to use the DOI lookup service offered by CrossRef: 
o On the Crossref homepage, paste the article title into the ‘Metadata search’ box. 
o Look for the correct, matching article in the list of results. 
o Click Actions > Cite 
o Alongside 'url =' copy the URL between { }. 
o Provide as follows, e.g.: https://doi.org/10.7196/07294.937.98x 
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APPENDIX 2: Data Capture Sheets 
Date of Birth YYYY - MM - DD 
Folder number   
Age at diagnosis   
VARIABLE KEY DESCRIPTION 
  
VARIABLE KEY DESCRIPTION 
Ethnicity 
1 Asian 
HBcIgG 
0 Not tested 
2 Black 1 Positive 
3 Coloured 2 Negative 
4 White 
HBcIgMG 
0 Not tested 
Gender 
1 Female 1 Positive 
2 Male 2 Negative 
Mode of 
transmission 
0 Unknown 
Hep A IgG 
0 Not tested 
1 Transfusion of blood products 1 Positive 
2 Intravenous drug use 2 Negative 
3 Parenteral or percutaneous 
HCV 
genotype 
1 Genotype 1 
4 Sexual encounter 2 Genotype 2 
5 Dental/orthodontic/surgical procedure 3 Genotype 3 
6 Mother-to-child transmission 4 Genotype 4 
IL28-B (allele) 
0 Not tested 5 Genotype 5 
1 CC 6 Genotype 6 
2 CT 
Genotype 
subtype 
1      a 
3 TT 2      b 
Sexual 
orientation 
0 Unknown 3      c 
1 Heterosexual 4      d 
2 MSM 5      e 
HBsAg 
0 Not tested    
1 Positive    
2 Negative    
VARIABLE KEY DESCRIPTION VALUE 
HCV VL IU/ml 
0 Not tested  
  Numerical value   
HCV log VL 
0 Not tested  
  Numerical value   
HIV 
0 Not tested  
1 Positive  
2 Negative  
CD4 
0 Not tested  
  CD4 count   
Blood 
Results 
Numerical 
values 
Blood 
Results 
Numerical 
values 
Blood 
Results 
Numerical 
values 
Blood 
Results 
Numerical 
values 
TBr   GGT   WCC   Tf sats%   
CBr   ALT   Plts   Ferritin   
TPr   AST   AFP   HBA1C (%)   
Alb   INR   Fe      
ALP   Hb   Tf      
Page 1 of 2 
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VARIABLE KEY DESCRIPTION VARIABLE KEY DESCRIPTION 
Diabetes mellitus 
1 Yes 
Treatment duration 
1 24 weeks 
2 No 2 48 weeks 
Raised BMI >30 
0 Unknown 3 72 weeks 
1 Yes 4 Other 
2 No 
PCR 4 
0 Not applicable 
ETOH 
1 Yes 1 Positive 
2 No 2 Negative 
ALD 
1 Yes 
PCR12 
0 Not applicable 
2 No 1 Positive 
NAFLD 
1 Yes 2 Negative 
2 No 
PCR24 
0 Not applicable 
Haemophilia 
0 Not a haemophiliac 1 Positive 
1 Haemophilia A 2 Negative 
2 Haemophilia B 
PCR48 
0 Not applicable 
HFE genes 
0 Not tested 1 Positive 
1 Negative 2 Negative 
2.1 C282Y homozygous 
PCR72 
0 Not applicable 
2.2 C282Y heterozygous 1 Positive 
3.1 H63D homozygous 2 Negative 
3.2 H63D heterozygous 
SVR 
0 Not applicable 
Porphyria plasma scan 
0 Not tested 1 Yes 
1 Positive 2 No 
2 Negative 
Treatment side-effects 
0 Not applicable 
Liver biopsy 
1 Yes 1 Yes 
2 No 2 No 
Metavir activity score 
0 No active inflammation 
Side effects experienced 
0 Not applicable 
1 Minimal inflammation 1 Neutropaenia 
2 Moderate 2 Anaemia 
3  Severe inflammation 3 Thrombocytopaenia 
4 Very severe inflammation 4 Bicytopaenia 
5 Not applicable 5 Pancytopaenia 
Metavir fibrosis score 
0 No fibrosis 6 Psychiatric 
1 Minimal fibrosis 7 Cytopaenia and psychiatric (7) 
2 Scarring 8 Rash (8) 
3 Bridging fibrosis 
G-CSF (eg. Neupogen)
0 Not applicable 
4 Cirrhosis 1 Yes 
5 Not applicable 2 No 
Steatosis 
0 Not applicable 
EPO (eg. Recormon) 
0 Not applicable 
1 Yes 1 Yes 
2 No 2 No 
Iron 
0 Not applicable 
Telapravir used 
0 Not applicable 
1 Yes 1 Yes 
2 No 2 No 
Treated or Not Treated 
1 Yes 
Other DAA used 
0 Not applicable 
2 No 1 Yes 
2 No 
Page 2 of 2 
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